GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Yield10 Bioscience Inc (OTCPK:YTENQ) » Definitions » Financial Strength

YTENQ (Yield10 Bioscience) Financial Strength : 0 (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Yield10 Bioscience Financial Strength?

Yield10 Bioscience has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

GuruFocus does not calculate Yield10 Bioscience's interest coverage with the available data. Yield10 Bioscience's debt to revenue ratio for the quarter that ended in Jun. 2024 was 1.55. As of today, Yield10 Bioscience's Altman Z-Score is -214.51.


Competitive Comparison of Yield10 Bioscience's Financial Strength

For the Agricultural Inputs subindustry, Yield10 Bioscience's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yield10 Bioscience's Financial Strength Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Yield10 Bioscience's Financial Strength distribution charts can be found below:

* The bar in red indicates where Yield10 Bioscience's Financial Strength falls into.


;
;

Yield10 Bioscience Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Yield10 Bioscience's Interest Expense for the months ended in Jun. 2024 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2024 was $-3.20 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.09 Mil.

Yield10 Bioscience's Interest Coverage for the quarter that ended in Jun. 2024 is

GuruFocus does not calculate Yield10 Bioscience's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Yield10 Bioscience's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.701 + 1.087) / 1.8
=1.55

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Yield10 Bioscience has a Z-score of -214.51, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -214.51 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Yield10 Bioscience  (OTCPK:YTENQ) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Yield10 Bioscience has the Financial Strength Rank of 0.


Yield10 Bioscience Financial Strength Related Terms

Thank you for viewing the detailed overview of Yield10 Bioscience's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Yield10 Bioscience Business Description

Traded in Other Exchanges
N/A
Address
19 Presidential Way, Woburn, MA, USA, 01801
Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Richard William Hamilton director 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320
Willie Loh director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801
Charles B Haaser officer: VP Fin and CAO
Lynne H Brum officer: VP Planning and Comms 21 ERIE STREET, CAMBRIDGE MA 02139
Kristi Snell officer: VP Research & CSO C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801
Anthony J Sinskey director C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139
Sherri M. Brown director C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801
Oliver P Peoples director, officer: Pres & CEO C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Joseph H Shaulson director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Celeste Beeks Mastin director 21 ERIE STREET, CAMBRIDGE MA 02139
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
William P Scully 10 percent owner C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038